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Abstract
Highly active antiretroviral therapy (HAART) has offered a promising approach for controlling HIV-1 replication in infected
individuals. However, with HARRT, HIV-1 is suppressed rather than eradicated due to persistence of HIV-1 in latent viral
reservoirs. Thus, purging the virus from latent reservoirs is an important strategy toward eradicating HIV-1 infection. In this
study, we discovered that the daphnane diterpene gnidimacrin, which was previously reported to have potent anti-cancer
cell activity, activated HIV-1 replication and killed persistently-infected cells at picomolar concentrations. In addition to its
potential to purge HIV-1 from latently infected cells, gnidimacrin potently inhibited a panel of HIV-1 R5 virus infection of
peripheral blood mononuclear cells (PBMCs) at an average concentration lower than 10 pM. In contrast, gnidimacrin only
partially inhibited HIV-1 64 virus infection of PBMCs. The strong anti-HIV-1 R5 virus activity of gnidimacrin was correlated
with its effect on down-regulation of the HIV-1 coreceptor CCR5. The anti-R5 virus activity of gnidimacrin was completely
abrogated by a selective protein kinase C beta inhibitor enzastaurin, which suggests that protein kinase C beta plays a key
role in the potent anti-HIV-1 activity of gnidimacrin in PBMCs. In summary, these results suggest that gnidimacrin could
activate latent HIV-1, specifically kill HIV-1 persistently infected cells, and inhibit R5 viruses at picomolar concentrations.
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Introduction
Human immunodeficiency virus type I (HIV-1) is the retrovirus
that causes acquired immunodeficiency syndrome (AIDS). The
AIDS pandemic is a serious public health problem for many
countries in the world. Many drugs have been developed for AIDS
therapy. The highly active antiretroviral therapy (HAART) that
combines 3 to 4 anti-retrovirals has been successful in controlling
HIV-1 replication in infected individuals. HAART has been
shown to reduce plasma viral loads to undetectable levels in many
HIV-1 infected patients [1,2]. Although HAART can effectively
control plasma viremia in many patients, the virus is suppressed
rather than truly eradicated [3–6]. Persistent HIV-1 infection,
especially in viral reservoirs, remains a challenge for effective
AIDS therapy. In addition, other drawbacks, such as toxicity and
side effects, often compromise the effectiveness of HAART. Thus,
development of treatment regimens using novel drugs with
potential to eradicate HIV-1 from its reservoirs is a major goal
of current AIDS therapy.
Daphnane diterpenoids are natural products with various
biological activities [7]. Highly oxygenated daphnane diterpenoids
were shown to inhibit HIV-1 infection at low micromolar
concentrations [8,9]. Gnidimacrin is a daphnane diterpene that
can be isolated from different plants in Thymeleaceae [10–14]. It
exhibited potent anti-cancer cell activity through activation of
protein kinase C. Gnidimacrin shares some structural similarity to
other anti-HIV-1 diterpenes, such as prostratin (12-deoxyphorbol-
13-acetate), DPP (12-deoxyphorbol-13-phenylacetate), and inge-
nol derivatives (Figure 1a). Prostratin is a tigliane diterpene that
was well documented for its anti-HIV-1 activity [15–17].
Prostratin is a non-tumour promoting phorbol ester that can
inhibit HIV-1 infection, and activate HIV-1 replication in latent
infection cell models. Thus, prostratin has been considered as a
drug candidate to purge HIV-1 from latent reservoirs. Similar to
prostratin, DPP is also a tigliane diterpene that was shown to
potently inhibit HIV-1 at nanomolar concentrations [18]. In
addition to the tigliane diterpenes, ingenane diterpene derivatives
were reported to have anti-HIV-1 activity comparable to that of
DPP [19,20]. The anti-HIV-1 activity of these compounds was, at
least in part, due to their ability to activate protein kinase C and
down-regulate HIV-1 receptors, CD4 and chemokine receptors
[16–20].
We have recently discovered that daphnane diterpenes,
including gnidimacrin, exhibited potent anti-viral activity against
the 64 virus NL4-3 replication in MT4 cell lines [21]. However,
their effect against HIV-1 primary isolates, mechanism of action,
and ability to activate latent HIV-1 remain to be determined.
Among the daphnane diterpenes, gnidimacrin was chosen for this
study because it has been well characterized for its anti-cancer cell
activities [10–14]. This study demonstrates that gnidimacrin
activated HIV-1 production from chronically infected cell lines,
ACH-2 and U1, at picomolar concentrations. In addition,
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26677gnidimacrin is a low picomolar HIV-1 R5 virus inhibitor that is
thousands fold more potent than prostratin. Prostratin is currently
the most well studied leading protein kinase C activator for
adjuvant therapy toward HIV-1 eradication. Our results suggested
that gnidimacrin targets protein kinase C beta to down regulate
CCR5 and CD4 for the potent anti-HIV-1 R5 activity.
Materials and Methods
Materials
All the HIV-1 primary isolates used in this study were obtained
from the NIH AIDS Research and Reagent Program. The anti-
CD4 mAb OKT4 was provided by Dr. Celia LaBranche, Duke
University, NC. The anti-CXCR4 mAb 12G5 and the anti-CCR5
mAb clone 45531 were obtained from the NIH AIDS Research
and Reagent Program for FACS analyses. Gnidimacrin is
provided by Dr. Wei Li, Toho University, Japan. Prostratin was
purchased from LC Laboratories, Woburn, MA. The protein
kinase C inhibitor, enzastaurin, was purchased from LC
laboratories, Woburn, MA. ACH-2, U1, U937, and MT4 cell
lines were obtained from the NIH AIDS Research and Reagent
Program. Human PBMCs were prepared from whole blood
obtained from the American Red Cross, Charlotte, NC.
Antiviral assay
Anti-HIV activity of the tested compounds against NL4-3
infection of MT4 cells was determined using a p24 production
assay. To determine anti-viral activity, the virus at a multiplicity of
Figure 1. Gnidimacrin activated HIV-1 production in chronically infected cells at picomolar concentrations. (a) Chemical structures of
gnidimacrin and prostratin. (b) Activation of HIV-1 production by gnidimacrin and prostratin. ACH-2 or U1 cells were treated with gnidimacrin or
prostratin at various concentrations for two days. Each data point in the figure represents the mean +/2 standard deviation of three independent
experiments.
doi:10.1371/journal.pone.0026677.g001
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cells in the presence of various concentrations of the compounds.
On day four post-infection, culture supernatant was harvested and
assayed for p24 using an ELISA kit from PerkinElmer. Drug
concentration that inhibits HIV-1 p24 production by 50% is
defined as the EC50 of the compounds. EC50 was determined with
a non-linear regression analysis using the Biosoft software,
Calcusyn.
Determination of the anti-HIV-1 activity against primary
isolates
A peripheral blood mononuclear cell (PBMC) assay was used to
evaluate the antiviral activity of the tested compounds against a
panel of HIV-1 primary isolates [22]. Human PBMCs were
isolated from whole blood and CD8 cells were depleted by using
Dynabeads purchased from Invitrogen. The CD8-depleted
phytohemagglutinin (PHA) stimulated PBMCs were infected with
virus at a multiplicity of infection (MOI) of 0.001 TCID50/cell in
the presence of various concentrations of the compounds. The
infected cells were cultured at 37uC for four days at which time
50% of the culture suspension was removed and fresh medium
containing appropriate concentrations of the compounds was
added. The culture supernatants were collected at day seven post-
infection for p24 assays.
Determination of the effect of enzastaurin on the anti-
HIV-1 activity of gnidimacrin
To determine whether PKC beta plays a role in the anti-HIV-1
activity of gnidimacrin, CD8-depleted PHA activated PBMCs
were pre-treated with various concentrations of enzastaurin for
2 hours. The enzastaurin treated PBMCs were then infected with
HIV-1 BaL in the presence of various concentrations of
enzastaurin and 0.1 nM of gnidimacrin or 0.5 uM of prostratin
in 100 ul of RPMI medium supplement with 20% FCS, IL-2
(10 U/ml), penicillin (100 U/ml), and Streptomycin (100 U/ml).
Fresh medium (100 ul) containing appropriate reagents was added
to each well on day 4 post infection. The culture supernatants were
assayed for p24 on day 7 post infection.
Determination of the cytotoxicity of the compounds
Compounds were tested for cytotoxicity against different cell
types. Cell lines at 1610
5 cells/ml, or PHA-activated PBMCs at
1610
6 cells/ml, were added to each well in a 96-well plate in the
presence of various concentration of the tested compounds for an
indicated period. Cell viability was determined by using a
Promega cytotoxicity assay kit, CellTiter-GloH Luminescent Cell
Viability Assay, following the manufacturer’s instruction. The
drug concentration that results in a 50% decrease in viable cells is
defined as the IC50 of a compound. The selectivity of a compound
(selectivity index or therapeutic index) is defined as IC50/EC50.
FACS analysis of HIV-1 receptors
MT4 cells or PBMCs were treated with gnidimacrin or
prostratin for various times. The cells were then incubated for
30 min on ice with primary antibodies against CD4, CXCR4, or
CCR5 in phosphate buffer saline (PBS) with 1% fetal bovine
serum (FBS). The primary antibody was removed by washing the
cells twice in PBS with 1% FBS. These cells were incubated for
30 min on ice with FITC-conjugated secondary antibody (BD
Biosciences, WI). Cells were washed three times and fixed with 1%
formaldehyde-PBS before analysed with a FACSCaliber cell sorter
(Becton-Dickinson, CA). The level of each receptor on cell surface
was expressed as % control which is defined as 1006 (MFIc-
MFIb/MFI0-MFIb), where MFI0 is the mean fluorescence intensity
in the absence of a compound, MFIc is the mean fluorescence
intensity in the presence of the test compounds, and MFIb is the
background mean fluorescence intensity when the primary
antibodies were not used in the assays.
Results
Gnidimacrin potently activated HIV-1 production from
chronically infected cells
ACH-1 and U1 cells were HIV-1 chronically infected cell lines
that have been used as in vitro cell models for HIV-1 latent
infection [23,24]. U1 cells were derived from the monocytic U937
cells chronically infected with HIV-1 and ACH-2 cells were HIV-1
chronically infected T cells derived from the lymphoblastoid cell
line CEM. The cells were treated with gnidimacrin or prostratin at
various concentrations for two days. In agreement with previous
reports [16,17], the non-tumour promoting phorbol ester
prostratin activated HIV-1 production in both ACH-2 and U1
cells at sub-micromolar concentrations (Figure 1b). On the other
hand, gnidimacrin activated HIV-1 production from both cell
lines at picomolar concentrations (Figure 1b). Although both
prostratin and gnidimacrin can activate HIV-1 production from
these latent HIV-1 infection model cells, gnidimacrin is at least
2,000-fold more potent than prostratin.
Gnidimacrin potently inhibited NL4-3 infection of MT4
cells at picomolar concentrations
Gnidimacrin was tested against the 64 virus NL4-3 infection of
MT4 cells at various concentrations. The HIV-1 RT inhibitor AZT,
one of the most common antiretroviral drugs used in clinic, and
prostratin, the most well studied non-tumour promoting phorborloid
for targeting HIV-1 reservoir,were used as controls in the same assays.
Gnidimacrin inhibited NL4-3 replication by 50% (EC50)a ta n
extremely low concentration of 31 pM (Figure 2a). In comparison, the
EC50s for AZT and prostratin were 20 nM and 175 nM, respectively.
Thus, gnidimacrin was greater than 5,000-fold more potent when
compared to prostratin. Gnidimacrin was also greater than 500-fold
more potent than AZT in the antiviral assays (Figure 2a).
Gnidimacrin down regulated CD4 and CXCR4 on MT4
cells
Gnidimacrin was previously reported to be a protein kinase C
agonist (13). It has been shown that protein kinase C agonists, such
as prostratin, can down regulate CD4 and CXCR4 [20]. To
determine whether down regulation of CD4 and CXCR4 is
responsible for the anti-HIV-1 activity, MT4 cells were treated
with various concentrations of gnidimacrin for one day. The
surface expressions of CD4 and CXCR4 on MT4 cells were
subsequently analysed with a fluorescence activated cell sorter
(FACS). The results indicated that gnidimacrin down regulated
both CD4 and CXCR4 expression on MT4 cells in a dose
dependent manner (Figure 2b). CD4 is relatively sensitive to
gnidimacrin when compared to CXCR4. Gnidimacrin down
regulated CD4 by approximately 90% at 1 nM. Higher
concentrations of the compound did not further increase CD4
down regulation (Figure 2b; additional file 1: Figure S1). On the
other hand, gnidimacrin down regulated CXCR4 by approxi-
mately 80% at 5 nM and higher concentrations of the compound
did not further increase CXCR4 down regulation.
These results are consistent with the notion that down
regulation of the viral receptors could be responsible for the
anti-viral activity of gnidimacrin. However, it should be noted that
Effect of Gnidimacrin on HIV-1 Replication
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gnidimacrin at 50 pM only down regulated CD4 and CXCR4 by
approximately 25%. It is possible that partial down regulations of
both CD4 and CXCR4 result in a synergistic effect to achieve the
potent inhibition of NL4-3 infection of MT4 cells. It is also
possible that other unknown mechanisms could play a role in the
inhibitory activity of gnidimacrin.
Gnidimacrin exhibited highly selective cytotoxicity
against HIV-1 chronically infected cells
Gnidimacrin is known to have anti-cancer cell activity.
Gnidimacrin was shown to selectively inhibit the growth of some
lung cancer and leukemic cell lines at sub-nanomolar concentra-
tions [11]. Therefore, the effects of gnidimacrin on the growth of
various cell types used in this study including peripheral
mononuclear cells (PBMCs), the leukaemia cell line MT4, and
the promonocytic cell line U937, were evaluated. The concentra-
tion of gnidimacrin that inhibited cell growth by 50% (IC50) was
greater than 2.5 uM for PBMCs, MT4, and U937 cells (Figure 3).
Thus, inhibition of HIV-1 replication by gnidimacrin in MT4 cells
was highly selective with a selectivity index (IC50/EC50) over
8610
4. In contrast, the HIV-1 chronically infected cells, U1 and
ACH-2, were very sensitive to the cytotoxic effect of gnidimacrin.
The IC50s of gnidimacrin against ACH-2 and U1 cells are
0.12 nM and 0.25 nM, respectively. Since U1 cells were derived
from the monocytic U937 cells, the markedly increased sensitivity
of U1 cells to gnidimacrin suggesting that activation of HIV-1
replication by the compound was likely responsible for the
cytotoxicity.
Gnidimacrin inhibited HIV-1 BaL infection of PBMCs at
low picomolar concentrations
HIV-1 uses CD4 and a co-receptor, CCR5 or CXCR4, for
entry into susceptible cells. It is well documented that the
predominant HIV-1 strains (R5 viruses) isolated from acutely
infected individuals use CCR5 for entry [25]. As shown in Figure 2,
gnidimacrin exhibited potent inhibitory activity against HIV-1
NL4-3 infection of MT4 cells. NL4-3 is an64 virus and MT4 is a
leukemic cell line that expresses CXCR4. To determine whether
gnidimacrin can inhibit both 64 and R5 viruses infection of
PBMCs, the 64 virus NL4-3 and the R5 virus HIV-1 BaL were
used to infect CD8-depleted PHA activated PBMCs. The anti-
HIV-1 protein kinase C agonist prostratin was used as a positive
control for the anti-viral activity of gnidimacrin. Unexpectedly,
gnidimacrin and prostratin only partially inhibited NL4-3
infection of the CD8-depleted PBMCs. Under the experimental
conditions, gnidimacrin was not able to inhibit NL4-3 replication
in PBMCs by more than 50% (Figure 4a). In contrast, gnidimacrin
potently inhibited HIV-1 BaL infection of the PBMCs by 50% at
42 pM. A similar pattern of inhibition of HIV-1 BaL was observed
Figure 2. Gnidimacrin inhibited HIV-1 NL4-3 infection at
picomolar concentrations. (a) MT4 cells were infected with NL4-3
in the presence of gnidimacrin, AZT, or prostratin for 4 days. The virus
replication in the absence of antivirals is defined as 100% (control) virus
production. Each data point in the figure represents the mean +/2
standard deviation of three independent experiments. (b) Down
regulation of CD4 and CXCR4 by gnidimacrin. MT4 cells were treated
with gnidimacrin at various concentrations for one day before FACS
analysis. The anti-CD4 monoclonal antibody OKT4 and the anti-CXCR4
monoclonal antibody 12G5 were used for the FACS analysis. The color
assignment to each assay condition is the same for both FACS panels. A
histogram of the FACS data on % receptor down regulation expressed
as ratio of mean fluorescence intensity (MFI) is available as additional
file 1 (Figure S1).
doi:10.1371/journal.pone.0026677.g002
Figure 3. Gnidimacrin exhibited highly selective cytotoxicity
against HIV-1 chronically infected cells. ACH-2, U1, and U937 cells
were treated with the compounds for three days before the cytotoxicity
was determined by using a Promega cell viability assay kit. MT4 and
PBMCs were treated with the compounds parallel to the antiviral assays
for 4 days and 7 days, respectively. The viability of the cells cultured in
the absence of the tested compounds is defined as 100% control. Each
data point in the figure represents the average of two independent
experiments.
doi:10.1371/journal.pone.0026677.g003
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approximately 5,000-fold less potent than gnidimacrin (Figure 4a).
Gnidimacrin down regulated CD4, CCR5, and CXCR4 on
PBMCs
To determine whether the anti-HIV-1 activity is correlated with
receptor down regulation on PBMCs, the HIV-1 receptors on
CD8-depleted PHA activated PBMCs were analysed with a
fluorescence activated cell sorter (FACS). All three HIV-1
receptors, CD4, CXCR4, and CCR5 were down regulated in
the presence of 1 nM gnidimacrin or 1 uM of prostratin
(Figure 4b). Gnidimacrin and prostratin exhibited a similar
pattern of HIV-1 receptor down regulation, except that gnidima-
crin was at least a thousand fold more potent than prostratin.
CCR5 was especially sensitive to gnidimacrin in that down
regulation of CCR5 approached 100% one day after gnidimacrin
treatment (Figure 4b; additional file 2: Figure S2). CCR5
Figure 4. Gnidimacrin inhibited R5 virus infection at picomolar concentrations. (a) HIV-1 BaL and NL4-3 were used to infect CD8-depleted
PHA activated PBMCs. The virus replication in the absence of antivirals is defined as 100% control virus production. Each data point in the figure
represents the mean +/2 standard deviation of three independent experiments. (b) Down regulation of HIV-1 receptors on PBMCs. CD8-depleted
PHA activated PBMCs were treated with 1 nM of gnidimacrin or 1 uM of prostratin for 24 hr or 48 hr. Background binding was performed with the
same protocol as other conditions, except that primary antibodies were not included in the assay. The color assignment to each assay condition is the
same for all six FACS panels. A histogram of the FACS data on % receptor down regulation expressed as ratio of mean fluorescence intensity (MFI) is
available as additional file 2 (Figure S2).
doi:10.1371/journal.pone.0026677.g004
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The strong down regulation of CCR5 could explain why the R5
virus HIV-1 BaL was extremely sensitive to gnidimacrin.
Similar to that observed on MT4 cells, 1 nM of gnidimacrin
down regulated CD4 on the PBMCs by approximately 90%. On
the other hand, CXCR4 on PBMCs was more sensitive to
gnidimacrin down regulation than that on MT4 cells (Figure 4b;
additional file 2: Figure S2). Yet, the 64 virus NL4-3 infection of
MT4 was very sensitive to gnidimacrin with an EC50 at 31 pM,
whereas NL4-3 infection of PBMCs was only partially inhibited by
gnidimacrin. The mechanism responsible for this discrepancy is
not clear. Nevertheless, HIV-1 infection of PBMCs reflects in vivo
HIV-1 infection more closely than the MT4 assay. Therefore, the
PBMC assay was used to further evaluate the effect of gnidimacrin
on HIV-1 primary isolates.
Gnidimacrin inhibited R5 HIV-1 primary isolates at low
picomolar concentrations
HIV-1 is a highly mutable virus with a highly diverse genomic
sequence. Therefore, it is critical for an anti-viral agent to have a
broad inhibitory activity against various HIV-1 primary isolates. A
panel of R5 and 64 HIV-1 strains from clade A to D was tested
for their sensitivity to gnidimacrin in a PBMC assay. The majority
of these HIV-1 strains were from an international panel of HIV-1
isolates representing major globally prevalent strains of genetically
and biologically characterized HIV-1 isolates [26]. Regardless of
their genetic subtypes, all of the twelve tested R5 HIV-1 strains
were very sensitive to gnidimacrin with EC50 ranging from 1 pM
to 50 pM (Table 1). The average EC50 of gnidimacrin is
approximately 9 pM against 12 R5 viruses. In contrast,
gnidimacrin did not effectively inhibit the four 64 viruses and
the dual tropic virus DH012. Similar to the inefficient inhibition of
NL4-3 shown in Figure 4, gnidimacrin was not effective against
the tested64 primary isolates. None of the four tested64 and the
dual tropic viruses was inhibited by more than 50% at a
gnidimacrin concentration as high as 1 uM under the experimen-
tal conditions.
Protein kinase C beta plays a key role in the anti-HIV-1
activity of gnidimacrin
The protein kinase C beta II was reported to be responsible for
the anti-cancer cell activity of gnidimacrin [13]. To test whether it
plays a role in the anti-HIV-1 activity of gnidimacrin, a protein
kinase C beta selective inhibitor enzastaurin [27] was used to
determine whether gnidimacrin targets the enzyme for the potent
anti-HIV-1 activity. Enzastaurin at various concentrations was
used to antagonize the antiviral activity of gnidimacrin against
HIV-1 BaL infection of PBMCs. The anti-HIV-1 activity of
0.1 nM gnidimacrin or 0.5 uM of prostratin was determined in
the presence of increasing concentrations of enzastaurin. HIV-1
replication was strongly inhibited by gnidimacrin or prostratin in
the absence of enzastaurin (Figure 5). Enzastaurin alone did not
affect HIV-1 replication or cell viability under the experimental
conditions. Enzastaurin at 2 uM was able to fully abrogate the
anti-HIV-1 activity of gnidimacrin or prostratin (Figure 5). This
result suggests that protein kinase C beta is the main protein kinase
C isozyme responsible for the anti-HIV-1 activity of gnidimacrin
in PBMCs.
Discussion
The results of this study demonstrate that the daphnane
diterpene gnidimacrin activated HIV-1 production from chroni-
cally infected cells, inhibited HIV-1 R5 virus infection of PBMCs,
and killed HIV-1 chronically infected cells at picomolar concen-
trations. Several other protein kinase C agonists were shown to
activate HIV-1 replication and down regulate HIV-1 receptors at
nanomolar concentrations. These protein kinase C agonists
include prostratin, P-13S, DPP, I3A, SJ23B, and bryostatin [15–
20,28–30]. Most of these compounds are natural products isolated
Table 1. Gnidimacrin inhibited R5 viruses at low picomolar
concentrations.
HIV-1 strains Clade
Gnidimacrin EC50
(pM) Co-receptor
KNH1088 A 3.1 CCR5
CM240/GS 022 CRF01_AE 3.5 CCR5
CAM0002BBY CRF02_AG 0.71 CCR5
Ba-L (85US_Ba-L) B 42.5 CCR5
33931N B 5.3 CCR5
BX08 B 3.7 CCR5
YU-2 B 4.5 CCR5
HIV-1 JRCSF B 20.5 CCR5
873 (90US_873) B 15.5 CCR5
SE364/GS 015 C 3.2 CCR5
20635-4 C 1.3 CCR5
A07412M1 D 12.8 CCR5
NI1052M1 CRF01_AE P* CXCR4
BK132/GS 009 B P* CXCR4
BZ 167 (GS 010) B P* CXCR4
NL4-3 B P* CXCR4
DH012 B P* CCR5/CXCR4
CD8 depleted PHA activated PBMCs were infected with HIV-1 for 7 days. The
EC50s in the table represent the average of two independent experiments. P*
denotes partial inhibition of the virus by gnidimacrin.
doi:10.1371/journal.pone.0026677.t001
Figure 5. Enzastaurin abrogated the anti-HIV-1 activity of
gnidimacrin and prostratin. CD8-depleted PHA activated PBMCs
were treated with enzastaurin at indicated concentrations for 2 hours.
The enzastaurin treated PBMCs were then infected with HIV-1 BaL in the
presence of various concentrations of enzastaurin and 0.1 nM of
gnidimacrin or 0.5 uM of prostratin. The culture supernatants were
assayed for p24 on day 7 post infection. The virus replication (p24) in
the presence of enzastaurin without gnidimacrin or prostratin is defined
as 100% control. Each data point in the figure represents the mean +/2
standard deviation of three independent experiments.
doi:10.1371/journal.pone.0026677.g005
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studied for its potential as an adjuvant therapeutic with HAART
to eradicate HIV-1 from its latent reservoirs. Successful semi-
synthesis of prostratin has further raised the interest of developing
this compound for potential HIV-1 eradication [31]. Thus,
prostratin was chosen as a control in this study for its regulatory
effect on HIV-1 replication.
The results of this study clearly indicate that gnidimacrin is at
least 1,000 fold more effective than prostratin in activation of
HIV-1 replication in the latently infected ACH-2 and U1 cells.
The effective doses for HIV-1 activation were equivalent to the
cytotoxic doses of both compounds. In contrast, U937, the
parental cell line of U1, was at least 1,000 fold less sensitive to the
cytotoxic effect of gnidimacrin. The differential sensitivity between
U1 and U937 to gnidimacrin suggests that activation of HIV-1
replication could potentially eliminate latently infected cells.
Gnidimacrin was also at least 1,000 fold more potent than
prostratin in inhibiting HIV-1 infection. Gnidimacrin was
particularly effective against R5 virus infection of PBMCs. The
average EC50 for gnidimacrin against the 12 tested R5 viruses was
approximately 9 pM. Such a potent inhibitory activity is likely
sufficient to inhibit the R5 viruses purged from latent viral
reservoirs.
Inhibition of R5 HIV-1 strains by gnidimacrin correlated with
down regulation of CCR5 on PBMCs (Figure 4b). CCR5 was
down regulated to background level on PBMCs, whereas CD4 and
CXCR4 were only partially down regulated by gnidimacrin.
Although the 64 virus NL4-3 replication in MT4 cells is very
sensitive to gnidimacrin, 64 virus replication in PBMCs was only
partially inhibited by gnidimacrin and prostratin. Down regulation
of HIV-1 receptors does not explain this discrepancy because
similar partial down regulation of CD4 and CXCR4 was observed
on both PBMCs and MT4 cells (Figure 2b, Figure 4b). One
possible explanation is that a small fraction of CD4 and CXCR4
on PBMCs, but not on MT4 cells, are sufficient for HIV-1
infection; as a result, partial down regulation of CD4 and CXCR4
potently inhibits HIV-1 infection of MT4 cells but is not effective
against 64 virus infection of PBMCs.
Like gnidimacrin, prostratin was able to completely inhibit R5
virus, but only partially inhibited 64 virus infection of PBMCs in
this study (Figure 4). The fact that gnidimacrin was ineffective
against all tested five viruses that use CXCR4 for entering PBMCs
further support the notion that CCR5 down regulation is a key
mechanism responsible for the potent anti-R5 virus activity.
Although the anti-HIV-1 activity of prostratin in cell lines is well
documented, the effect of prostratin on HIV-1 infection of PBMCs
is not conclusive. Prostratin was shown to inhibit both R5 and 64
virus infection of activated PBMCs [32]. In contrast, it has also
been shown that prostratin and the ingenol I3A were inactive
against NL4-3 (an 64 virus) infection of activated PBMCs [20]. It
is possible that inhibition of 64 virus infection by gnidimacrin is
dependent on cell types and the activation states of the cells.
Protein kinase C is a large family with four conventional
isozymes PKCa, PKCbI, PKCbII and PKCc; four novel
isozymes, PKCd,- e,- g, and -h; the atypical isozymes PKCf
and PKCi [33]. Enzastaurin is a selective inhibitor for PKCbI and
PKCbII [27]. The strong antagonistic effect of enzastaurin on the
anti-HIV-1 activity of gnidimacrin suggests that protein kinase C
beta is the major protein kinase C isozyme responsible for the
potent anti-HIV-1 activity. We propose that gnidimacrin inhibits
HIV-1 by activating protein kinase C beta, which in turn strongly
down regulates CCR5 and partially internalizes CD4 and
CXCR4.
In conclusion, the results of this study suggest that protein kinase
C beta is the target of gnidimacrin. Activation of protein kinase C
beta by gnidimacrin causes internalization of HIV-1 receptors
CD4, CXCR4, and CCR5, which prevents HIV-1 from entering
the cells. Gnidimacrin is an extremely potent HIV-1 regulator that
activates HIV-1 replication in chronically infected cells and
inhibits R5 HIV-1 strains at low picomolar concentrations. The
potent dichotomous activities make gnidimacrin an attractive
adjuvant therapeutic candidate for the possibility of HIV-1
eradication. Future challenges in studying this potent anti-HIV-1
agent include identification of the specific cellular pathways that
impart this extremely potent dichotomous activity of gnidimacrin.
Supporting Information
Figure S1 Dose-dependent down regulation of CD4 and
CXCR4 on MT4 cells by gnidimacrin. MT4 cells were
treated with gnidimacrin at various concentrations for one day
before FACS analysis. The anti-CD4 monoclonal antibody OKT4
and the anti-CXCR4 monoclonal antibody 12G5 were used for
the FACS analysis. The level of each receptor on the cell surface
was expressed as % control which is defined as 1006 (MFIc-
MFIb/MFI0-MFIb), where MFI0 is the mean fluorescence intensity
in the absence of a compound, MFIc is the mean fluorescence
intensity in the presence of the test compounds, and MFIb is the
background mean fluorescence intensity when the primary
antibodies were not used in the assays.
(TIF)
Figure S2 Down regulation of CCR5, CXCR4, and CD4
on PBMCs by gnidimacrin. CD8-depleted PHA activated
PBMCs were treated with 1 nM of gnidimacrin or 1 uM of
prostratin for 24 hr or 48 hr. The X-axial labels, such as CCR5-
gnidimacrin, denote the relative level of a receptor in the presence
of gnidimacrin or prostratin.
(TIF)
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